Skip to main content
. 2018 Jul 19;36(26):2684–2692. doi: 10.1200/JCO.2017.77.6112

Fig 4.

Fig 4.

Most frequently reported adverse events. The percentage of patients with grade 1 and 2 and grade 3 to 5 events are shown for all adverse events that occurred in > 5% of patients in either treatment group as grade 3 to 5 events. 7+3, standard-of-care cytarabine plus daunorubicin chemotherapy; CPX-351, dual-drug liposomal encapsulation of cytarabine and daunorubicin.

HHS Vulnerability Disclosure